110 related articles for article (PubMed ID: 23962030)
1. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.
Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T
Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030
[TBL] [Abstract][Full Text] [Related]
2. Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig.
Higashi E; Ando A; Iwano S; Murayama N; Yamazaki H; Miyamoto Y
Biopharm Drug Dispos; 2014 Sep; 35(6):313-20. PubMed ID: 24752421
[TBL] [Abstract][Full Text] [Related]
3. S-equol glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice.
Isobe T; Ohkawara S; Ochi S; Tanaka-Kagawa T; Hanioka N
Food Chem Toxicol; 2019 Sep; 131():110542. PubMed ID: 31163218
[TBL] [Abstract][Full Text] [Related]
4. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
[TBL] [Abstract][Full Text] [Related]
5. Wogonin glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice.
Hanioka N; Isobe T; Tanaka-Kagawa T; Ohkawara S
Xenobiotica; 2020 Aug; 50(8):906-912. PubMed ID: 32005083
[TBL] [Abstract][Full Text] [Related]
6.
Hanioka N; Isobe T; Tanaka-Kagawa T; Jinno H; Ohkawara S
Drug Chem Toxicol; 2022 Jul; 45(4):1565-1569. PubMed ID: 33187449
[TBL] [Abstract][Full Text] [Related]
7. Regioselective glucuronidation of daidzein in liver and intestinal microsomes of humans, monkeys, rats, and mice.
Hanioka N; Ohkawara S; Isobe T; Ochi S; Tanaka-Kagawa T; Jinno H
Arch Toxicol; 2018 Sep; 92(9):2809-2817. PubMed ID: 30014295
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes.
Hong X; Zheng Y; Qin Z; Wu B; Dai Y; Gao H; Yao Z; Gonzalez FJ; Yao X
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28925930
[TBL] [Abstract][Full Text] [Related]
9. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
Naritomi Y; Nakamori F; Furukawa T; Tabata K
Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
[TBL] [Abstract][Full Text] [Related]
10. Naringenin glucuronidation in liver and intestine microsomes of humans, monkeys, rats, and mice.
Isobe T; Ohkawara S; Ochi S; Tanaka-Kagawa T; Jinno H; Hanioka N
Food Chem Toxicol; 2018 Jan; 111():417-422. PubMed ID: 29198856
[TBL] [Abstract][Full Text] [Related]
11. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Gill KL; Houston JB; Galetin A
Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method.
Kadono K; Koakutsu A; Naritomi Y; Terashita S; Tabata K; Teramura T
Xenobiotica; 2014 Jun; 44(6):511-21. PubMed ID: 24329478
[TBL] [Abstract][Full Text] [Related]
13. Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10.
Lu D; Dong D; Wu B
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):989-998. PubMed ID: 30049229
[TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
15. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
[TBL] [Abstract][Full Text] [Related]
16. Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs.
Nishimuta H; Nakagawa T; Nomura N; Yabuki M
Xenobiotica; 2013 Nov; 43(11):948-55. PubMed ID: 23593983
[TBL] [Abstract][Full Text] [Related]
17. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
Kaji H; Kume T
Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.
Komura H; Iwaki M
Drug Metab Rev; 2011 Nov; 43(4):476-98. PubMed ID: 21859377
[TBL] [Abstract][Full Text] [Related]
19. Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates.
Wang M; Lu J; Li J; Qi H; Wang Y; Zhang H
Food Chem Toxicol; 2014 Feb; 64():135-43. PubMed ID: 24296138
[TBL] [Abstract][Full Text] [Related]
20. Species differences in UDP-glucuronosyltransferase activities in mice and rats.
Shiratani H; Katoh M; Nakajima M; Yokoi T
Drug Metab Dispos; 2008 Sep; 36(9):1745-52. PubMed ID: 18505787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
